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1028-9 Usefulness of Cutting Balloon for Treating Very 
Calcified or Undilatabie Coronary Lesions 
mGov, Thierry LefBvrs, Yves Louvard, Pierre Dumas, Christophe Loubsyre, Jean- 
Franqois PiBchaud, Marie-Claude Morice. lnstituf Card~ovasculaire Paris Sud, Massy 
FrallCa. 
Background: Percutaneous coronary intervention (PCI) of highly calcified or undilatable 
coronary lesions remains a difficult problem. Rotative atherectomy has been shown to be 
a useful tool in this setting but remains technically demanding and associated with a non 
negligible rats of complications. The purpose of this study was to evaluate the role of 
Cutting (C) balloon in this sening. 
Methods: Systematic use of C balloon in the treatment of undilatable lesions (resistant to 
balloon inflation > 16 atm or balloon rupture) or primary intention in highly calcified 
lesions was retrospectively evaluated from a database of 1,666 consecutive PCI (1999- 
2oM)). 
Results: During this period C balloon was used in 105 patients (77 with in stent resteno- 
sis and 26. with undilatable or highly calcified lesions). These 26 patients (1.5% of PCI) 
had a mean age of 73.9+6.5 years, 71.4% were male. Indication of PCI was unstable 
angina in 57.1 % of cases, stable angina in 39.3% and silent ischemia in 3.5%. Indica- 
tions of C balloon were undilatable lesions in 14 lesions and highly calcified lesions in 20. 
C balloon primaty crossing failure occurred in 6134 lesions (16%): 4 lesions were suc- 
cessfully predilated using an undersized balloon catheter and C balloon crossing was 
obtained. One lesion was successfully predilated using very high pressure (22 atm.) and 
then stented. In the remaining lesions predilatation failed. Successful opening of the 
lesion after C balloon crossing was obtained in 31/32 lesions using a mean C balloon 
size of 2.90+0.40 mm and inflation pressure of 9.7+3.2 atm. Rotablator was used suc- 
cessfully in 2 lesions : 1 after balloon predilatation failure and 1 after failure to open the 
lesion with C balloon. A stent was used in 33.&t lesions and successfully positioned and 
deployed in all cases. Angiographic success (residual lesion < 30% and final TIMI 3 flow) 
was obtained in 100% of cases. MACE during hospitalization occurred in 7.1% of cases : 
non-Q-wave Ml 7.1%. Q-wave Ml O%, emergency CABG 0% and death 3.5%. 
Conclusion: This study shows that the cutting balloon can be a useful tool for treating 
highly calcified or undilatabls lesions. The limitation of the device is a relatively low rate 
of lesion crossing success. 
1028-l 0 Which Is Better for Lesions With Arterial Positive 
Remodeilng: Stenting or Atherectomy? Results of Stent 
Versus Atherectomy Randomized Trial 
vTsuchikane. Tomoko Kobayashi, Mokoto Sakurai, Yoshihiro Takeda, Nobuhisa 
Awata, Tohru Kobayashi, Osaka Medical Center for Cancer and Cardiovascular 
Diseases, Osaka, Japan. 
Intravascular ultrasound (IVUS) studies have shown pre-interventional arterial positive 
remodeling (PAPR) causes worse clinical outcomes after coronary stenting. START 
(STent versus Athsrectomy Randomized Trial) was a randomized trial comparing angio- 
graphic and IVlJS outcomes between primary stenting and aggressive DCA. This study 
aimed to examine ths impact of PAPR on restenosis between the two devices. One hun- 
dred twenty-two lesions were randomly assigned to stent (62 lesions) or DCA group (60 
lesions). Palmaz-Schatz stent(s) was implanted with high pressure post-dilatation in the 
stent group. Aggressive dsbulking using IVUS was performed in ths DCA group. There 
were no differences in baseline characteristics, and all procedures were successful with- 
out complications. Six month follow-up (Fu) angiography was performed in 116 lesions. 
Eligible serial IVUS images were available in 110 lesions (stent:56, DCA:52). PAPR was 
defined as pre lesion I reference vessel area > 1.0. Twenty-seven lesions of the stsnt 
group and 16 lesions of ths DCA group had PAPR. Quantitative coronary angiography 
and ultrasound results are shown in the table. Restenosis was defined as diameter 
stenosis at Fu > 50%. In conclusion, stenting more accelerates nsointimal proliferation 
compared with aggressive DCA, and it particularly shows a higher restsnosis rate in 
lesions with PAPR. These results suggest that plaque debulking should be preferred to 
primary stenting for lesions with PAPR. 
Results 
Non Positve Remodeling 
DCA Stent 
Reference (mm) 3.37kO.39 3.2OiO.45 
Post MLD (mm) 2.67+0.36 2.77+0.44 
Fu MLD (mm) 2.27t0.64 2.02iO.63 
Neointima area (mm’) 1.24t2.24 2.76kl.63 
Restenosis rate 19.4% 19.4% 
MLD=minimal lumen diameter, ‘Pro.05 vs DCA 
Positve Remodeling 
DCA Stent 
3.16i0.35 3.29*0.42 
2.67a0.43 2.62X1.34 
2.41i0.66 1.66*0.71’ 
1.34k2.04 3.59+2.14’ 
12.5% 46.1%’ 
1028-11 Anglographic indicators for the Use of Distal Protection 
Devices in Saphenous Vein Graft lnterventlons 
Nicholas &I;nr. Ross Prpic, Richard E. Kuntz, Michelle Fitzpatrick, Satyendra Giri, 
Unsal Kaya, Donald S. Bairn, Jeffely J. Popma, Brigham and Women’s Hospital, Eoslon, 
Massachusetts. 
Background: Many new intracoronaly devices have been developed to reduce the risk 
of percutaneous intewention in saphenous vein grafts (SVG). The safety and efficacy of 
some of these devices has previously been proven. It is however unclear if there are par- 
ticular subgroups of patients that are at higher risk of complications and would thus 
derive greater benefit from the use of such devices. Methods: We analyzed baseline and 
post procedural angiograms obtained from 691 patients with 806 lesions undergoing 
SVG intervention in a trial investigating the efficacy profile of the PercuSurge Guard- 
WireTM distal protective device. Lesion morphology analysis included TIMI thrombus 
score (TS) and degree of SVG degeneration (SVGD). The combined angiographic com- 
plications (AC) analyzed were no-reflow, distal embolization. abrupt closure and reduced 
TIMI flow post procedure. Results: AC wem significantly associated with thrombus 
scores greater than 2, (TS 2-3: AC 4&5%;noAC 32.3% P=O.o075 and TS 4-5: AC 12.1%; 
noAC 4.5% P= 0.0075). Less than 25% SVGD was significantly associated with less AC 
(SVGDc25%: AC 33.3%, no AC 57.0% P=O.O002). Conversely, 26-50% SVGD was sig- 
nificantly associated with more complications (SVGD 26-50%: AC 45.5%; noAC 26.6% 
p=O.OOll). Although a trend was observed, more than 51% SVGD was not significantly 
associated with higher AC, which may in part be explained by the small sample size of 
patients with such morphologic characteristics (SVGD 51-75%: AC 13.6%: noAC 11.4% 
P=NS and SVGD >75%: AC 7.6%; noAC 5.0% P=NS). Conclusions: The presence of 
angiographically evident thrombus and more extensive SVG degeneration at baseline 
increase the risk of angiographic complications during SVG intervention, emphasizing 
the impoltance of distal protection devices, especially in these complex lesion subsets. 
1028-12 Cutting Balloon Limits Plaque Shift in Bifurcation 
Lesions 
Ramchandra S. Veerapaneni, mW. HungChin Ho, UAS, Birmingham, Alabama. 
BACKGROUND: Current percutaneous treatments of bifurcation lesions(BL) are fre- 
quently complicated by snow ploughing effect of plaque and compromise of the 
untreated nontarget adjacent branch (AB). We evaluated the effect of cutting balloon 
angioplasty (CB) in these lesions. 
METHODS: From June ‘00 to May ‘01, 65 SL (by Duke classification) were treated with 
CB. There were 46 type 3b or 4, ostial BL (with ~30% stenosis in AS) (Group A) and 23 
type la or 3a, true BL (with 30.50% stenosis of AB) (Group 6). Quantitative measure- 
ments of main vessel, target lesion vessel & untreated AB were made. Plaque shift effect 
was measured as the change of minimal luminal diameter(MLD) of AB before and after 
CB. 
RESULTS: There were 46 males and ths mean age was 64 + 11 .There were 39 hyper- 
tensives, 29 diabetics,21 with prior infarcts, 17 with ventricular dysfunction.19 with previ- 
ous bypass surgery and 46 with previous angioplasty. There were 36 left anterior 
descending, 30 circumflex and 7 right coronary artery bifurcation lesions. Stents were 
used in 12 lesions. Significant plaque shift after CB required further intervention in 3 
group A and 4 group B patients. Inhospital outcomes included 3 non Q infarcts, 3 core- 
nary perforations managed conservatively and no emergency bypass or death. CON- 
CLUSION: CB causes no significant plaque shift or compromise of AB in most ostial & 
true BL and should be considered one of the treatments of choice for BL. 
Reference 
vessel (mm) 
MLD (mm) % Stenosis 
Pre- post- Prs- post- 
Target lesion(GroupA) 1.92io.35 0.76M.37 1.59fo.25^ 60114 15k3’ 
Plaque shift effect 2.04x).51 1.66fo.65 1.63tio.38# 19i7 13f4# 
Main vessel 2.75f0.55 2.32i0.95 2.36+0.65# 16*5 6-t3# 
Target lesion(GroupB) 2.14i0.56 0.79ztO.61 1.52fo.10’ 65f4 14C2 
Plaque shift effect 2.2010.73 1.11+0.45 0.96*0.29# 47f7 43f7# 
Main vessel 2.64m.60 1.77m.74 1.95*0.29+? 37*7 17f3 
Paired t-test: ’ p< 0.05, # p = nonsignifcant 
1028-13 intervention in Saphenous Vein Grafts: A Predictive 
Model of Mortality Based on Clinical Presentation of 
5,899 Consecutive Cases in the ACC-NCDR Registry 
!_lovd W. Klein, Ralph G. Brindis, Michael Kutcher, Kathleen Hewitt, William S. 
Wsintraub, for the ACC-NCDR Registry, Rush-Presbyterian St. Luke’s Medical Center, 
Chicago, Illinois. 
Background and Methods: Percutaneous coronary intervention (PCI) in saphenous 
vein grafts (SVG) may have unpredictable and potentially catastrophic outcomes due to 
the inherent instability of degenerative graft atheroma and thrombus. A predictive model 
based on clinical presentation would aid in evaluating benefits versus risk in these 
patients. We utilized the ACC-NCDR registry, consisting of data from 145 institutions 
between 1996-2000, to analyze outcomes in 5,699 SVG procedures and to develop a 
nomogram to predict mortality based on clinical presentation. 
Rssulta: In this patient cohort, 47% had had previous PCI, 25% were having an acute 
infarction, and 72% had Class Ill or IV angina. At least one stent was placed in 75% of 
cases, and 20% had multi-site PCI. Anglographic success was attained in 93%. There 
was a 1.46% in-hospital mortality rate. The acuity of the procedure was the single most 
predictive factor: elective procedures carried 0.6% mortality, urgent cases 1.2%, emer- 
gent 6.9%, and salvage 31.6% (p<O.OOOl). Multivariate analysis revealed six variables to 
be predictive: age (p<O.OOOl, odds ratio 1.62 (1.41, 2.34)) - 10 points for age 50 and 10 
points for each lo-year increment; presence of shcck (p<O.OOOl, 6.54 (3.31, 12.9)) - 64 
points; emergent or salvage indication (p~0.0001. 7.91 (4.29, 14.6)) - 71 points Or 16.6 
(5.4, 64.2) 100 points; renal failure (p=O.O003, 3.04 (1.69, 5.54)) - 39 pOints; and ejecfion 
fraction (EF) ~60% (p=O.OO2.0.79 (0.66, 0.92)) - 6 points EF &O% and 6 points for every 
10% decrement. A nomogram consisting of a score comprised of 323 points was highly 
predictive of mortality, with a mean absolute error of 0.002 of predicted vs. observed risk, 
up to 15% mortality rate. A score of less than 95 points predicted 1% or less risk, 152 
points 5% risk, 177 points 10% risk, and more than 193 points 15% risk. 
Conclusions: The volume and diversity of the ACC-NCDR registry provides a format for 
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developing risk adjustment mortality models. The in-hospital moriality in SVG PCI is reli- 
ably predicted by incorporating only a few clinical variables known prior to Starting the 
procedure. The ability to accurately assess risk will aid in patient counseling and case 
selection. 
1028-14 Does the Beneficial Effect of Distal Protectlon in 
Saphenous Vein Graft Interventions Vary With Lesion 
Length? A SAFER (Saphenous Vein Graft Angioplasty 
Free of Emboli Randomized) Substudy 
Greoorv Ft. Giuolia, Ross Prpic. Donald E. Cutlip. Jeffrey J. Popma. Kalon L. Ho, 
Laura Mauri, Unsal Kaya, Dennis Wahr, Barry George, Donald S. Bairn. Richard E. 
Ku&, Harvard Clinical Research Institute, Boston, Massachusetts. St. Joseph Mercy 
Hospital, Ann Arbor, Michigan. 
Background: The SAFER trial demonstrated a dramatic reduction in Major Adverse 
Clinical Events (MACE: a composite of death, Ml or revascularfzation) acutely and at 30 
days following saphenous vein graft (SVG) percutaneous intervention (PCI) with the use 
of the Percusurge GuardWire TM distal protection device. This benefit was anributed to 
the prevention of distal migration of atherosclerotic debris with the device. 
Methods: We sought to evaluate if the reduction in MACE seen in the SAFER trial varied 
with the length of the treated lesion. We divided lesion lengths into quartiles and per- 
formed a stratified analysis to evaluate for effect modification by lesion length on the 
reduction in MACE with the GuardWireTM compared to patients treated with no distal pro- 
tection. 
Rasutts: Of the 751 lesions treated, longer lesions were associated with a higher inci- 
dence of MACE in both the control group (p=O.Oll) and GuardWireTM group (p=O.OOl). 
As demonstrated in the table, use of the GuardWireTM was associated with a reduction in 
MACE in each quartile of lesion length. With multivariable modeling, shorter lesions 
showed a trend toward a greater relative reduction in MACE with use of the Guard- 
WireTM (p=O.O97). 
Lesion 
Length 
Quartile 
(mm) 
z-22 
N 30.Day 30-Day Odds Ratio Relative P-value 
MACE MACE (95% Cl) Reduction 
Without With MACE 
GuardWire GuardWire 
166 23% 16% 0.72 22% 0.47 
(0.36-l .48) 
14.8-22 197 15% 10.5% 0.65 30% 0.39 
(0.28-l .52) 
10-14.6 167 17.2% 6.5% 0.45 51% 0.06 
(0.16-1.10) 
<lo 179 6.1% 2.2% 0.25 73% 0.09 
(0.05-l .26) 
Conclusion: The reduction in MACE seen with GuardWireTM occlusion balloon distal 
protection in SVG PCI is upheld regardless of the length of lesion being treated. There is 
a trend toward more relative benefit with the GuardWlreTM for shorter lesions despite the 
finding that shorter lesions convey a lower risk of MACE. 
1028-15 Supported Elective Angioplasty Procedures Without 
On-Site Cardiac Surgery Is Associated With Low Risk of 
Adverse Events 
KirkN.Garran, Henry T. Tmg, Mandeep Singh, Ryan J. Lennon, Katherine L. Boutchee, 
Joseph A. Dearani. Jack T. Cusma, Douglas L. Wood, David R. Holmes, Jr., Mayo Clinic, 
Rochester, Minnesota. 
Background: The safety of elective percutaneous coronary intervention (PCI) at commu- 
nity hospitals without on-site cardiac surgery is uncertam. 
Methods: A cooperative plan to support PCI was implemented by Mayo Clinic cardiolo- 
gists and cardiac surgeons at Saint Marys Hospital (SMH, tertiary care facility) and 
lmmanuel St Joseph’s Hospital (ISJ, no cardiac surgery). These hospitals are separated 
by 65 miles. Patient selection criteria (ACClAHA type A or Bl lesion type), contingently 
plans and a telecommunications network to support consultation between physicians and 
surgeons during PCI were developed. Success and complications observed at ISJ over 
the first 26 months of operation were compared to pts treated at SMH, matched for lesion 
type. Expected mortality risk was estimated using the New York State angioplasty data- 
base. 
Results: Between 3/99 and 7/01, elective PCI was performed in 206 pts at ISJ (stents in 
94.6%) and 690 similar pts at SMH @tents in 66.4%). Unmatched variables were similar, 
except SMH pts had more severe angina, myocardial injury, prior bypass surgery or heart 
failure. Abciximab was used in 76% ISJ and 23% SMH pts (p<O.OOl). Procedures were 
successful in 99.5% ISJ and 97.2% SMH pts (p=O.O53). No patient required transport for 
urgent cardiac or vascular surgery. Table shows estimated and observed mortality at 
both hospitals. 
Follow-up for at least 6 months showed no differences in late outcomes. 
Conclusions: Supported elective PCI in selected low risk patients is safe. On-site cardiac 
surgical services may no longer be required. 
Location Expected Deaths Actual Deaths CABG 
SMH (n=690) Frequency 11.0 5 3 
Percent (95% C.I.) 1.60 (0.9, 2.9) 0.72 (0.2, 1.7) 0.43 (<O.l, 1.3) 
ISJ (n=206) Frequency 2.7 1 0 
percent (95% C.I.) 1.30 (0.4, 4.2) 0.49 (<O.l, 2.7) 0.00 (0, 1.8) 
1028-I 6 Percutaneous Interventions of the Internal Mammary 
Artery GraR: Immediate and Long-Term Clinical 
Outcome 
BBoccalane, Paulino Sousa, Remy Choussat. Bruno Farah. Rossella Gonilla, Jean 
Fajadet, Jean Paul Bouhnoure, Jean Marco, Clinique Pasteur. Toulouse, France 
Background: Safety of percutaneous treatment of the internal mammary artery (IMA) 
graft has been reported in small numbers of patients series. However, information is 
needed regarding utility of stent implantation. radial approach and long term clinical out- 
comeMethods: We report the immediate results and long-term clinical outcome of per- 
cutaneous coronary intervention (PCI) of the IMA graft. Between June 1995 and June 
2000,136 consecutive pts underwent PCI of the IMA graft, by either balloon angioplasty or 
stenting. These procedures represent 0.9 % of the 9649 PCI procedures performed in 
our institution in this period. We analysed clinical and procedural predictors of survival 
and event-free survival defined as freedom from death, myocardial infarction and target 
vessel coronary revascularization. Results: Clinical Follow-up ( mean 41.3k17.6 
months) was obtained in all the patients. The procedure was performed by radial 
approach in 39 and by femoral approach in 49. IMA graft was Len for 60 PTS and Right 
for 26 PTS. A total of 93 lesions (76 located at the distal anastomosis, 9 at the body of 
the graft and 6 at the ostium) were treated: 61 by balloon, 29 by stenting after predilata- 
tion and 3 by direct stenting. Mean lesion length, reference vessel diameter and prepro- 
cedural percentage of stenosis were 11.22 6.2 mm, 2.6+0.4 mm and 61+ 6 96 
respectively. Procedural success was achieved in all patients. In-hospital MACE included 
only one Cl wave myocardial infarction. Three years overall survival was 90.6 * 4.3% 
(mean f SEE) and event free survival 67.9+4.2%. At 1 and 3-years follow-up, freedom 
from any coronary revascularization was 67.3+4.2% and 61.9*5.1% respectively. Neither 
lesion location on the graft, nor stem implantation were found to be independent predic- 
tors of cardiac events at follow-up.Conclusfons: This report suggests that PCI of IMA 
graft, performed by radial or femoral approach, is associated with low procedural risk and 
satisfactory long term clinical outcome and can be an effective alternative to surgery. 
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1029-17 FGF-1 Gene Therapy Plasmid for Patients With Critical 
Limb Ischemia: Final Results 
SD. Anthony Comerota, Nicolas Chronos, John Laird, Rafael Sequeira, 
Bruce Konke, Craig Kent, Juha-Pekka Salenius, Maria Pyle, Richard Pilsudski, Hennepin 
County Medical Center, Minneapolis, Minnesota, University of Minnesota, Minneapolis, 
Minnesota. 
Angiogenic growth factors represent a novel treatment for patients (Pts) with critical limb 
&hernia (CLI) who are not amenable to standard revascularization. We evaluated the 
safety and tolerability of increasing doses of IM delivery of a nonviral plasmid encoding 
fibroblast growth factor (NVlFGF) in Pts with CLI. Methods: 51 Pts with CLI (rest pain 
and/or non-healing ulcers) and not eligible for revascularization based on angiography < 
1 month were randomized to receive IM NVlFGF into the ischemic thigh and calf. 27 Pts 
received 1 treatment (500 to 16,000 ug.) and 24 pts received 2 treatments at 0 and 3 
weeks (5OQ to 6000 ug x2). FGF-1 levels, plasmid bicdistribution, transcutaneous oxygen 
(TcPO& ankle brachial index (ABI), pain assessment by a visual analog scale, and ulcer 
healing were assessed at baseline, 2 , 3 , and 6 months. Results: For the 33 completed 
Pts (Final results ll/Ol), NVlFGF was well tolerated with no serious adverse side effects 
related to the NVlFGF including no death, myocardial Infarction, or cancer. FGF-1 was 
not detected and there was only limited and transient biodistribution of plasmid in 
plasma. A significant reduction was noted in pain and ulcer size. with a significant 
increase in TcP02 and a trend for ABI compared to baseline values (see table). Conclu- 
sion: In the first trial using FGF gene therapy for Pts with CLI. NV1 FGF was well tolerated 
with encouraging initial clinical results. These results suppolt a randomized, double blind, 
placebo controlled trial in Pts with CLI using NV1 FGF. 
Change from BL 
(p=) 
2 Months 
3 Months 
6 Months 
Pain 
-51 
(.OOOl) 
-50 
(.OOOl) 
-60 
(.OOOl) 
Ulcer Size 
NA 
NA 
-53% 
(.002) 
TcPO2 
d2 
(.OOl) 
+16 
(.OOOl) 
Not Done 
ABI 
+0.07 
(.007) 
+0.09 
(.005) 
CO.08 
(.07) 
